Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
DNAtrix logo — company profile

DNAtrix

Founded 2005 United States San Diego, United States 3 employees Venture round Total: $57.08M Biotechnology, Health Care

General Information

Company Name DNAtrix
Founded Year 2005
Location United States San Diego, United States
Employees 3
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with DNAtrix. To contact DNAtrix, visit dnatrix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DNAtrix compare?

A PDF of DNAtrix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DNAtrix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DNAtrix

DNAtrix is a biotech company pioneering virus-driven immunotherapies for cancer treatment. This United States-based startup's proprietary adenovirus platform utilizes an engineered version of the common cold virus to selectively infect and destroy cancer cells while sparing healthy cells. Their lead product, DNX-2401, is poised to begin a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. FDA Fast Track and Rare Pediatric Disease designations have also been granted for its evaluation in a Phase 1 study for diffuse intrinsic pontine glioma. Additionally, DNX-2440, their second product candidate, is entering a Phase 1 clinical study for colorectal and other cancers with liver metastasis. Notably, the company has secured a $15.53M Venture Round investment from key investors Morningside Ventures and Mercury Fund in September 12, 2018.

Business keywords: Biotech, Immunotherapy, Cancer Treatment, Oncolytic Virus, Glioblastoma, Clinical Research, Virology, Molecular Biology, Drug Development, Adenovirus, Rare Pediatric Disease, Phase 3 Clinical Study, Brain Tumor, Metastasis, Investment

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $15.53M -
12 Sep 2018
Convertible Note Undisclosed 1
Texas Halo Fund
Texas Halo Fund
01 Dec 2016
Grant $2.00M 1
U.S. Food and Drug Administration
04 Aug 2016
Series B $20.00M 4
Targeted Technology Texas Halo Fund
Targeted Technology, Texas Halo Fund +2
14 Oct 2014
Grant $10.80M 1
Cancer Prevention and Research Institute of Texas
24 Feb 2014
Debt Financing $1.54M 1
DFJ Mercury
07 Nov 2013
Debt Financing $840.00K 1
DFJ Mercury
27 Aug 2013
Debt Financing $160.00K 1
DFJ Mercury
01 Jun 2013
Seed Round $885.62K -
03 Aug 2012
Seed Round $4.50M 1
DFJ Mercury
30 Jan 2012

View All 13 Funding Rounds

DNAtrix Alternatives & Competitors

View All Alternatives
DNAtrix vs
Enterome
Enterome France

Delivering the promise of immunotherapy

Venture round
49 employees
Biopharma, Biotechnology
DNAtrix vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
DNAtrix vs
Valo Therapeutics Ltd
Valo Therapeutics Ltd Finland

Reinventing Cancer Immunotherapy

11 employees
Biotechnology, Health Care
View all alternatives

FAQ About DNAtrix

DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The c...
DNAtrix was founded in 2005.
DNAtrix is headquartered in San Diego, United States.
DNAtrix operates in Biotechnology and Health Care. Its work centres on Biotech, Immunotherapy, Cancer Treatment and Oncolytic Virus.
DNAtrix has approximately 3 employees.
DNAtrix has completed 13 funding rounds, raising a total of $57.08M. The latest funding stage is Venture round.
Top alternatives and competitors to DNAtrix include Enterome, Farcast Biosciences, Valo Therapeutics Ltd, Wuhan YZY Biopharma Co. Ltd., Circio Holding ASA . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DNAtrix and Enterome are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DNAtrix, https://bouncewatch.com/company/dnatrix-1, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout